RxDoctor Payments Data

Pamela Stuckey, NP

Family · Charleston, SCNPI 1609299858

Payments from drug & device makers

$7,413in general payments, 2019–2025

Across 318 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$852
  • Merck$606
  • E.r. Squibb & Sons, L.L.C.$476
  • Lilly USA, LLC$368
  • AstraZeneca$352
  • Incyte Corporation$345
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$6,81492%
  • Education$4005%
  • Other$1993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,413 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,069
Medicare patients
314
Services billed
1,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide17$363,414
IbrancePalbociclib17$270,492
JakafiRuxolitinib Phosphate18$251,488
ErleadaApalutamide14$195,438
ImbruvicaIbrutinib11$163,398
TasignaNilotinib Hcl12$61,928
Abiraterone Acetate15$46,235
EliquisApixaban43$40,661
Imatinib Mesylate11$14,403
Exemestane13$1,961
Letrozole38$1,429
Hydroxyurea15$677
Gabapentin25$394
Anastrozole17$384
Escitalopram Oxalate34$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$201$363,41417 claims
PfizerIbrance, Eliquis$197$311,15360 claims
Incyte CorporationJakafi$345$251,48818 claims
Johnson & JohnsonErleada$203$195,43814 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$33$163,39811 claims
NovartisTasigna$852$61,92812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →